FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number: Estimated average burden	3235-0287						
hours per response:	0.5						

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HANNAH ALISON L. (Last) (First) (Middle) 9490 NEOGENOMICS WAY					2. Issuer Name and Ticker or Trading Symbol NEOGENOMICS INC [NEO] 3. Date of Earliest Transaction (Month/Day/Year) 08/10/2023									Relationship of Reporting (Check all applicable) X Director Officer (give title below)			Person(s) to Issuer 10% Owner Other (specify below)	
(Street) FORT MYERS (City)	FL (State)		3912 (ip)	4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)									dividual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									v	Amount		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock														107,433			D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount Securities Underlyi Derivative Security 3 and 4)		rlying	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported	e s illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title		Amount or Number of Shares		Transact (Instr. 4)			
Stock Option (Right to Buy)	\$11.6							06/01/201	9 0	6/01/2023		mmon tock	3,017		3,01	7	D	
Stock Option (Right to Buy)	\$22.52							06/06/202	0 0	6/06/2026	Cor St	mmon tock	4,269		4,269		D	
Stock Options (Right to Buy)	\$28.54							05/28/202	1 0	5/28/2027		mmon tock	3,448		3,44	8	D	
Stock Option (Right to Buy)	\$40.9							06/02/202	2 0	6/02/2028		mmon tock	3,714		3,714	4	D	
Stock Option (Right to Buy)	\$8.1							06/10/202	3 0	6/10/2029		mmon tock	13,882		13,88	2	D	
Stock Option (Right to Buy)	\$14.82	08/10/2023		A		8,353		08/10/202	4 0	8/10/2033		mmon tock	8,353	\$0	8,35	3	D	
Restricted Stock Unit	\$0	08/10/2023		A		11,336		08/10/202	4	(1)		nmon tock	11,336	\$0	11,33	6	D	

Explanation of Responses:

1. Once vested, the shares of common stock are not subject to expiration.

Remarks:

/s/ Ali Olivo, Attorney-in-Fact
** Signature of Reporting Person

08/14/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).